Who We Are – A Timeline of Vision and Growth
2018 – Planting the Seed of a Vision
Cilo Cybin is founded with a bold purpose: to transform lives through accessible, effective medical cannabis products. We become the first entity in South Africa to secure both cultivation and manufacturing licenses for medical cannabis.
Our state-of-the-art indoor cultivation facility is accredited for GACP (Good Agricultural and Collection Practices) and cGMP (current Good Manufacturing Practices) by SAHPRA, ensuring global-standard quality and regulatory trust from inception.
2018–2021 – Building the GMP Cannabis Platform
Cilo Cybin Pharmaceutical establishes itself as a leader in GMP-certified medical cannabis, producing high quality Cannabis API’s, final products as cannabis flower.
Our cold ethanol extraction process, combined with filtration, winterisation, solvent recovery, and decarboxylation, distillation, delivers high-purity oils with complete traceability from cultivation through to final product.
This vertically integrated model ensures consistency, compliance, and reliability, making us the largest South African producer of THC distillate and full spectrum oil. Today supplying high grade Cannabis API’s such as THC Full Spectrum, THC Distillate, CBD Isolate, Non Crystallisation, and Distillate, CBN, CBG, CBC, THCV, CBDV Isolates and many many more.
November 2022 – IPO Attempt
Cilo Cybin Holdings pursued an IPO on the JSE to raise capital for expansion. The offering was not successful, and the company refunded all investors in full. While a setback, it marked an important turning point in refining our capital markets strategy.
June 2024 – A Historic Listing
Cilo Cybin Holdings achieved a breakthrough by becoming the first cannabis-focused SPAC to successfully list on the JSE AltX Board.
This milestone was backed by APLS Global from Malaysia, positioning Cilo Cybin Holdings as a vehicle for strategic acquisitions and biotechnology growth. The listing reinforced our leadership as pioneers of regulated medical cannabis in South Africa.
2025 – Strategic Acquisition & Main Board Transition
In 2025, Cilo Cybin Holdings issued a Circular announcing:
JSE approval for the acquisition of Cilo Cybin Pharmaceutical at a R845 million valuation.
The transaction was independently reviewed and deemed fair by BDO.
Plans to de-SPAC, de-list from AltX, and transition to the JSE Main Board, pending shareholder approval.
Once the transaction is voted through, the combined value of Cilo Cybin Holdings and Cilo Cybin Pharmaceutical will exceed R1 billion, cementing our position as the most valuable medical cannabis company in South Africa and a leading force in the emerging global cannabis industry.
Our Story in Summary
2018: Founded with a vision; first in South Africa with cultivation + manufacturing licenses.
2018–2021: Built a vertically integrated GMP cannabis platform; largest local producer of THC distillate and full spectrum oil.
2022: IPO attempt – refunded investors after unsuccessful raise.
2024: Successfully listed Cilo Cybin Holdings (CCC) on JSE AltX, with APLS Global backing.
2025: Announced acquisition of Cilo Cybin Pharmaceutical (R845m valuation); combined entity valued above R1 billion; JSE-approved transition to the Main Board pending shareholder approval.
Our Accreditations
State of the art, indoor medical-grade cannabis cultivation, in accordance to Good Agricultural and Collection Practices (GACP).
Cannabis Cultivation
Good Manufacturing Practices (GMP) cannabis processing in South Africa and manufacturing of medical-cannabis products for the local and international markets.
Quality Manufacturing
Products & Services
We offer a wide range of Products and Services in the medical cannabis sector. Browse these by selecting the area of interest below.
